Evidence map›Paper›PMID 31645892›Full record

ArticleLung cancer management2019

Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer.

Mari Tone, Takehiro Izumo, Nobuyasu Awano, Naoyuki Kuse, Minoru Inomata, Tatsunori Jo, Hanako Yoshimura, Shingo Miyamoto, Hideo Kunitoh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mari ToneDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Takehiro IzumoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Nobuyasu AwanoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Naoyuki KuseDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Minoru InomataDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Tatsunori JoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Hanako YoshimuraDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Shingo MiyamotoDepartment of Medical Oncology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Hideo KunitohDepartment of Medical Oncology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. PATIENTS &

methods18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy.

resultsThe overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%.

conclusionThe efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.

Indexed as

immune checkpoint inhibitorNSCLCsalvage chemotherapy

Identifiers

PMID31645892
PMCPMC6802711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.